# Lumira Ventures

> Lumira Ventures is a VC fund backing Biotechnology and Health Care. See 119 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Toronto, Canada
- Total investments: 119
- Last investment: Jun 2026
- Lead investor: 30%
- Last fund: Oct 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/lumira-ventures
- X (Twitter): https://twitter.com/LumiraVentures
- Website: http://www.lumiraventures.com

Lumira Ventures is a VC fund in Toronto focused on Biotechnology and Health Care. With a 30-year reputation as a leading North American healthcare and life sciences venture capital firm, with offices in Toronto, Montreal, Vancouver and Boston, Lumira Ventures collaborates with and invests in entrepreneurial management teams to build best-in-class, innovation-centric biotherapeutic and medical device companies that are meetingsignificant unmet needs and creating transformation impact in communities worldwide.Since 1989, Lumira Ventures has invested in over 100 healthcare companies and currently has a portfolio of 30+ active investee companies located in Canada and the United States.

## Contacts

5 contacts available for Lumira Ventures. Shizune tracks 10 team members at Lumira Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lumira-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.9M–$105M |
| Series B | $12M–$75M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 45 | 38% |
| Health Care | 32 | 27% |
| Medical | 22 | 18% |
| Therapeutics | 21 | 18% |
| Medical Device | 16 | 13% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 22 | 18% |
| Series B | 16 | 13% |
| Funding Round | 12 | 10% |
| Series C | 11 | 9% |
| Series D | 10 | 8% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 34 | 29% |
| Canada | 24 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Baye Galligan, M.A., HBA | Associate | 0 | https://shizune.co/investors/profile/baye-galligan |
| Benjamin Rovinski | Managing Director | 10 | https://shizune.co/investors/profile/beni-rovinski |
| Brian J. Underdown, Ph.D. | Venture Partner | 1 | https://shizune.co/investors/profile/brian-j-underdown |
| Daniel Hetu | Managing Director | 11 | https://shizune.co/investors/profile/daniel-hetu |
| Lu Han | Director, Business Development Asia Pacific | 2 | https://shizune.co/investors/profile/lu-han |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $50M | Series B | Jun 18, 2026 |  |
| Contraline | Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible. | $92.5M | Series B | Jun 02, 2026 |  |
| Nervonik | Nervonik is a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system. Nervonik is focused on advancing clinical research and achieving regulatory milestones to bring its innovative therapies to market. | $52.5M | Series B | Apr 27, 2026 |  |
| Congruence Therapeutics | Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $39.5M | Venture - Series Unknown | Mar 19, 2026 |  |
| Nocion Therapeutics | Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation. | $23M | Series B | Jan 07, 2026 |  |
| Thryv Therapeutics | Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs. |  |  | Sep 17, 2025 |  |
| Congruence Therapeutics | Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $32M | Venture - Series Unknown | Sep 04, 2025 |  |
| HistoSonics | HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. |  | Private Equity | Aug 07, 2025 |  |
| Corvia Medical | Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009and headquartered in Andover, Massachusetts. | $55M |  | Jun 17, 2025 |  |
| Puzzle Medical Devices | Puzzle Medical is developing the ModulHeart, a modular percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure who are not candidates for heart transplant or surgical mechanical circulatory support. The device’s modular design allows for hemodynamic support through multiplepumps anchored in parallel in the descending aorta. The design is expected to increase accessibility by enabling safe percutaneous implantation to support both renal and cardiac function, with low risk of bleeding, stroke, and pump thrombosis, while providing sustained symptom relief, reduced re-hospitalizations and improved overall quality of life. To date, Puzzle Medical has successfully:○ completed its first-in-human study with all patients experiencing improvements in cardiac and kidney function (2022); ○ completed a Seed financing round (2021); ○ built a strong Key Opinion Leaders committee (2021); ○ received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation (2021). | $30.2M | Series A | Apr 08, 2025 |  |

10 of 119 investments shown.

## Co-investors
- [Fonds de solidarité FTQ](https://shizune.co/investors/profile/fonds-de-solidarit-ftq) — VC Fund, 16 deals together
- [Amzak Health Investors](https://shizune.co/investors/profile/amzak-health-investors) — VC Fund, 8 deals together
- [adMare Bio Innovations](https://shizune.co/investors/profile/admare-bio-innovations) — VC Fund, 7 deals together
- [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 7 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 7 deals together
- [Viva BioInnovator](https://shizune.co/investors/profile/viva-biotech) — VC Fund, 7 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Biotech Investors in Canada](https://shizune.co/investors/biotech-investors-canada)
- [Biotech VC Funds in Canada](https://shizune.co/investors/biotech-vc-funds-canada)
- [Biotechnology Investors in Canada](https://shizune.co/investors/biotechnology-investors-canada)
- [Health Care Investors in Canada](https://shizune.co/investors/health-care-investors-canada)
- [Health Care VC Funds in Canada](https://shizune.co/investors/health-care-vc-funds-canada)

## FAQ

### What does Lumira Ventures invest in?

Lumira Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 119 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Lumira Ventures's check size?

Lumira Ventures typically joins rounds of $2.9M–$105M at Series A and $12M–$75M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Lumira Ventures participates in.

### How do I contact Lumira Ventures?

Public channels for Lumira Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Lumira Ventures?

The team at Lumira Ventures includes Baye Galligan, M.A., HBA (Associate), Benjamin Rovinski (Managing Director) and Brian J. Underdown, Ph.D. (Venture Partner), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co